수두 백신 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global varicella vaccines market size is expected to reach USD 7.77 Billion in 2034 from USD 4.22 Billion in 2025, growing at a CAGR of 7.02 during 2026-2034.This market is experiencing strong growth driven by increasing awareness about immunization and the prevention of infectious diseases. Varicella vaccines are used to protect against chickenpox, a highly contagious viral infection. The implementation of vaccination programs by governments and healthcare organizations is a major factor contributing to market expansion. Additionally, the growing focus on preventive healthcare is encouraging the adoption of vaccines across various regions.

Major drivers include rising healthcare awareness and the expansion of immunization programs. Governments are investing in vaccination campaigns to reduce the incidence of infectious diseases. The increasing availability of vaccines and improved distribution networks are also supporting market growth. Furthermore, advancements in vaccine development are enhancing efficacy and safety, encouraging wider adoption.

Looking ahead, the market is expected to benefit from continued investments in healthcare and research. The development of combination vaccines and improved storage solutions will enhance accessibility. Emerging markets are likely to witness significant growth due to increasing healthcare infrastructure and awareness. As global efforts to prevent infectious diseases continue, the varicella vaccines market is set for sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Vaccine Type

• Monovalent Varicella Vaccine
• Combination Varicella Vaccine

By Application

• Chickenpox Immunization
• Mumps, Measles, Rubella, and Varicella (MMRV) Immunization

By Age Group

• Pediatrics
• Adolescents and Adults

By Procurement

• Public
• Private

COMPANIES PROFILED

• Bio-Med, Changchun Changsheng Life Sciences Limited, GC Pharma, GlaxoSmithKline, Merck, Mitsubishi Tanabe Pharma Corporation, Novo Medi Sciences, Sanofi, Seqirus, Sinovac Biotech, SK Bioscience, Takeda Pharmaceutical Company Limited

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL VARICELLA VACCINES MARKET: BY VACCINE TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Vaccine Type
• 4.2. Monovalent Varicella Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Combination Varicella Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL VARICELLA VACCINES MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Chickenpox Immunization Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Mumps, Measles, Rubella, and Varicella (MMRV) Immunization Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL VARICELLA VACCINES MARKET: BY AGE GROUP 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Age Group
• 6.2. Pediatrics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Adolescents and Adults Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL VARICELLA VACCINES MARKET: BY PROCUREMENT 2022-2034 (USD MN and Million Doses)

• 7.1. Market Analysis, Insights and Forecast Procurement
• 7.2. Public Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.3. Private Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL VARICELLA VACCINES MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.2.1 By Vaccine Type
  • 8.2.2 By Application
  • 8.2.3 By Age Group
  • 8.2.4 By Procurement
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.3.1 By Vaccine Type
  • 8.3.2 By Application
  • 8.3.3 By Age Group
  • 8.3.4 By Procurement
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.4.1 By Vaccine Type
  • 8.4.2 By Application
  • 8.4.3 By Age Group
  • 8.4.4 By Procurement
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.5.1 By Vaccine Type
  • 8.5.2 By Application
  • 8.5.3 By Age Group
  • 8.5.4 By Procurement
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.6.1 By Vaccine Type
  • 8.6.2 By Application
  • 8.6.3 By Age Group
  • 8.6.4 By Procurement
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL VARICELLA VACCINES INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Bio-Med
  • 10.2.2 Changchun Changsheng Life Sciences Limited
  • 10.2.3 GC Pharma
  • 10.2.4 GlaxoSmithKline
  • 10.2.5 Merck
  • 10.2.6 Mitsubishi Tanabe Pharma Corporation
  • 10.2.7 Novo Medi Sciences
  • 10.2.8 Sanofi
  • 10.2.9 Seqirus
  • 10.2.10 Sinovac Biotech
  • 10.2.11 SK Bioscience
  • 10.2.12 Takeda Pharmaceutical Company Limited